IL6R and COVID-19: With regard to the analysis of 3924 COVID-19 patients admitted to ICU, and recruited among 4485 adults referring to 68 US hospitals, Gupta et al. demonstrated that the death risk resulted in being lower in participants treated with tocilizumab, when compared to subjects not undergoing drug therapy with this anti-IL-6R antagonist [72].